GFGiovanna Finzi

Giovanna Finzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giovanna Finzi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-electrophilic TRPA1 modulator MNP-021 protects neuronal and glial function from diabetes-associated glucotoxicity and neuroinflammation

    by Alessandro De Carli, Carolina Filipponi, Beatrice Polini, Veronica Sancho-Bornez, Emy Basso, Fabio Filippini, Angela Dardano, Francesca Sardelli, Simona Daniele, Martina Contestabile, et al.

  • Open Access

    The indolent nature of gastroblastoma. Report of an illustrative case with 28 years of follow-up showing previously unreported immunohistochemical and molecular features

    by Stefano La Rosa, Federica Branca, Giovanna Finzi, Laura Libera, Monica Leutner, Christoph Schubart, Abbas Agaimy

    We report the clinical, morphological, ultrastructural, and molecular features of a gastroblastoma diagnosed in a 27-year-old male describing some unreported findings that can help to better understand this very rare tumor. The clinical course lasting 28 years confirms the indolent nature of gastroblastoma, although the disease was metastatic to local lymph nodes and peritoneum at the time of diagnosis. The tumor displayed a predominant monophasic appearance, being composed of epithelial cells with only very rare spindle mesenchymal cells, confirmed at ultrastructural examination. Thorough immunohistochemical investigation demonstrated coexpression of cytokeratins (AE1/AE3, CAM5.2, CK8/18), podoplanin (D2-40), CD56, and NSE in absence of synaptophysin, chromogranin A, DOG1, CD117, CD34, SMA, desmin, vimentin, and S100. In addition, the expression of somatostatin receptor 2 A associated with positive octreoscan and 68Ga-DOTATOC PET imaging may suggest the use of this nuclear medicine approach for the staging of the tumor and to select patients for possible therapy with somatostatin analogues. The tumor was mismatch repair proteins proficient and did not show any mutation in all 60 genes investigated. Interestingly, targeted RNA sequencing identified a previously unreported TAC3::GLI1 fusion that expands the spectrum of genetic aberrations of gastroblastoma.

  • Gastric Amphicrine Carcinoma Showing Neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric Neuroendocrine Neoplasms

    by Amedeo Sciarra, Silvia Uccella, Philippe Hiroz, Ian Fournier, Vincent Soubeyran, Giovanna Finzi, Stefano La Rosa

    Amphicrine carcinomas are epithelial neoplasms composed of cells with co-existing exocrine-neuroendocrine phenotype and are challenging lesions from both diagnostic and therapeutic perspectives.Here, we report the case of a 63-year-old male patient with a gastric nodule that was endoscopically biopsied, revealing histological features of a type 3 well-differentiated gastric neuroendocrine tumor (NET). At imaging, the lesion was single and limited to the stomach, but did not present In-111Octreotide uptake, despite SSTR2A immunohistochemical expression. The patient underwent a wedge resection of the gastric wall, with a final pathological diagnosis of amphicrine carcinoma with pancreatic acinar cell and neuroendocrine features (pT1b). Predictive immunohistochemistry showed microsatellite stability and negative HER2 status. Hotspot targeted deep sequencing of 57 genes showed no somatic mutation, in agreement with the low mutational burden reported for gastric amphicrine carcinomas. Due to a low stage of the tumor and the poor performance status of the patient, no additional oncological treatment was administered. The patient was disease-free after 18 months.This unusual case highlights the importance of considering amphicrine carcinoma in the diagnostic work-up of gastric type 3 NET. This can be done by including in the immunohistochemical panel non-neuroendocrine markers, such as the pancreatic acinar cell and glandular ones. Correct pathological diagnosis is pivotal to determine the appropriate staging (NET vs exocrine one) for surgical and oncological management.


  • Open Access

    Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity

    by Rajendran Sanalkumar, Rui Dong, Lukuo Lee, Yu-Hang Xing, Sowmya Iyer, Igor Letovanec, Stefano La Rosa, Giovanna Finzi, Elettra Musolino, Roberto Papait, et al.

    Cell fate transitions observed in embryonic development involve changes in three-dimensional genomic organization that provide proper lineage specification. Whether similar events occur within tumor cells and contribute to cancer evolution remains largely unexplored. We modeled this process in the pediatric cancer Ewing sarcoma and investigated high-resolution looping and large-scale nuclear conformation changes associated with the oncogenic fusion protein EWS-FLI1. We show that chromatin interactions in tumor cells are dominated by highly connected looping hubs centered on EWS-FLI1 binding sites, which directly control the activity of linked enhancers and promoters to establish oncogenic expression programs. Conversely, EWS-FLI1 depletion led to the disassembly of these looping networks and a widespread nuclear reorganization through the establishment of new looping patterns and large-scale compartment configuration matching those observed in mesenchymal stem cells, a candidate Ewing sarcoma progenitor. Our data demonstrate that major architectural features of nuclear organization in cancer cells can depend on single oncogenes and are readily reversed to reestablish latent differentiation programs.


  • Open Access

    Mitochondrial alterations in Parkinson's disease human samples and cellular models

    by Mara Zilocchi, Giovanna Finzi, Marta Lualdi, Fausto Sessa, Mauro Fasano, Tiziana Alberio


  • Cushing’s Syndrome due to a Pancreatic Neuroendocrine Tumor Metastatic to the Ovaries: a Clinicopathological Description of a Case

    by Stefano La Rosa, Alessandro Marando, Fabio Ghezzi, Paolo Colombo, Giovanna Finzi, Carlo Capella

    We report the case of a 36-year-old woman with Cushing’s syndrome caused by a malignant unresectable neuroendocrine carcinoma of the pancreas that developed bilateral ovarian metastases 7 years after diagnosis. In November 2001, because of abdominal pain and jaundice, the patient underwent radiological investigations and exploratory laparotomy that demonstrated the presence of a 3-cm mass of the head of the pancreas, infiltrating the superior mesenteric vein, associated with enlargement of multiple abdominal lymph nodes and with a liver nodule. Histological examination of one lymph node and of the liver nodule demonstrated the presence of metastases from a well-differentiated neuroendocrine carcinoma showing corticotropin immunoreactivity. A few months later, the patient started to show the clinical symptoms of Cushing’s syndrome and underwent steroid-blocking ketoconazole therapy. The clinical endocrine picture was controlled until the end of 2008, when the endocrine symptoms of the Cushing’s syndrome worsened and bilateral ovarian tumors appeared. Hysteroannexectomy was performed and ovarian tumors were found to be metastases from a well-differentiated neuroendocrine carcinoma with morphological and immunohistochemical features overlapping those observed in 2002. The clinical situation worsened and the patient died in November 2009. The clinical aspects and the problems in the differential diagnosis are discussed.